Les meilleurs doctors en Israël pour votre Chimiothérapie du lymphome - TOP 16 des médecins

Le Dr Ram Ron est spécialisé en chimiothérapie des lymphomes au Centre médical Sourasky (Ichilov) et apporte une vaste expertise dans les cas complexes.

• Spécialisé en Obstétrique et Gynécologie – Médecine de la Reproduction
• Plus de 25 ans d'expérience dans les traitements médicaux
• Formation de perfectionnement (Fellowship) effectuée au Ronald O Perelman and Claudia Cohen Centre

Chef du service d'Oncohématologie Pédiatrique à l'Hôpital pour enfants Dana Dwek – Le Dr El Hasid est spécialisé dans les greffes de moelle osseuse et de sang de cordon ombilical. Il a effectué plus de 300 procédures.

• Plus de 50 articles de recherche publiés
• Plus de 40 communications lors de conférences
• Membre de l'Association Américaine d'Hématologie et de la Société Israélienne d'Hémato-oncologie Pédiatrique
• Formation de boursier (Fellowship) au City of Hope Hospital à Los Angeles

Le Dr Ron Ram a réalisé plusieurs centaines de greffes de cellules souches, démontrant sa profonde expertise dans le traitement du lymphome au Centre médical Sourasky.

• Certifié par le conseil (Board-certified) en médecine interne, hématologie et oncologie médicale
• Formation en fellowship au New York Medical College, Westchester Medical Center
• A publié plus de 30 articles scientifiques sur l'hématologie et l'oncologie
• A contribué à un chapitre d'un manuel médical

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Spécialisé(e) en transplantation de moelle osseuse – Le Dr Shapira apporte une expertise ciblée en chimiothérapie du lymphome au Centre médical Sourasky.

• Diplômé(e) de la faculté de médecine de l'Université hébraïque en 1999
• Spécialisation en médecine interne au Centre médical Hadassah
• Médecin senior en transplantation de moelle osseuse à Hadassah
• Parle couramment l'anglais et l'hébreu

31 ans d'expérience en oncohématologie – Le Dr Aviv est spécialisé en chimiothérapie des lymphomes au Sourasky Medical Center (Ichilov).

• Se concentre exclusivement sur les cancers du sang et les traitements des lymphomes
• Travaille dans l'un des principaux centres médicaux d'Israël
• Fournit des protocoles de chimiothérapie personnalisés

Le Dr Dror Levin est un expert de premier plan dans le domaine des troubles sanguins pédiatriques et du cancer des os. Il dirige le département d'hémato-oncologie au Centre médical Sourasky.

• Spécialisé dans le traitement du cancer des os (sarcome) chez les enfants
• Coordonne le traitement avec le département général d'oncologie-orthopédie
• Membre de l'Association israélienne d'hémato-oncologie pédiatrique (ISPHO)
• Formé en hématologie et oncologie pédiatriques au Centre médical pour enfants Schneider
• A étudié l'oncologie osseuse et des tissus mous à l'Institut orthopédique Rizzoli en Italie

Le Dr Herishanu Yair a remporté plusieurs prix pour ses recherches sur la leucémie lymphoïde chronique et l'hématologie au Centre médical Sourasky.

• Spécialisé en hématologie avec un accent sur le traitement de la leucémie
• A reçu le Prix de recherche pour jeune investigateur ainsi que d'autres distinctions honorifiques
• Membre des Associations israélienne et américaine d'hématologie
• Formation approfondie incluant des résidences en médecine interne et en hématologie

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Chef du service d'hématologie au Centre médical Hadassah – La Professeure Ben-yehuda a été pionnière dans la thérapie génique et les greffes de moelle osseuse pour le traitement du lymphome.

• Formation au Memorial Sloan-Kettering Cancer Center à New York
• Spécialisée dans le diagnostic moléculaire des cancers du sang
• Première femme doyenne de l'École de médecine Hadassah
• Lauréate du prix « Healing with the Heart Award »

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.